Ponatinib Hydrochloride Patent Expiration
Ponatinib Hydrochloride is used for treating various types of leukemia, including acute lymphoblastic leukemia, chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia. It was first introduced by Takeda Pharmaceuticals Usa Inc
Ponatinib Hydrochloride Patents
Given below is the list of patents protecting Ponatinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Iclusig | US11192895 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
Iclusig | US11192897 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
Iclusig | US11384086 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
Iclusig | US9493470 | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | Dec 12, 2033 | Takeda Pharms Usa |
Iclusig | US8114874 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | Jan 24, 2027 | Takeda Pharms Usa |
Iclusig | US9029533 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | Dec 22, 2026 | Takeda Pharms Usa |
Ponatinib Hydrochloride's Family Patents

Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List